1 story in the last 7 days
The latest kardigan news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks kardigan across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.

Heart drug developer Kardigan is targeting a $1.4 billion valuation in its U.S. initial public offering. The company is seeking to raise capital by selling shares to public investors. The IPO would value the biotech firm at approximately $1.4 billion.
Summaries by ByteBrief